Abstract: To reduce the risk of hormone therapy (, HT),, the use of, HT, requires strict exclusion of contraindications, including pregnancy, unexplained vaginal bleeding
breast cancer, sex hormone-related malignancies, active venous or arterial thromboembolic disease, severe hepatic or renal dysfunction, and some rare sex hormone-related diseases.
Some rare diseases related to sex hormones.
The indications for hormone therapy (, hormone, therapy, HT), are very broad.
The indications for the use of hormone therapy (hormone, therapy, HT) are very broad, and all symptoms and diseases associated with reduced estrogen levels are indicated.
However, contraindications to HT must be strictly controlled before use.
Contraindications to HT include
Known or suspected pregnancy, unexplained vaginal bleeding or endometrial hyperplasia, known or suspected
known or suspected pregnancy, unexplained vaginal bleeding or endometrial hyperplasia, known or suspected breast cancer, known or suspected sex hormone-related malignancy,6
known or suspected breast cancer, known or suspected sex hormone-related malignancy, active venous or arterial thromboembolic disease within 6 months, severe hepatic or renal dysfunction
Severe liver and kidney dysfunction, hematoporphyria, otosclerosis, systemic lupus erythematosus, progesterone related disease, or other conditions within 6 months.
SLE, progesterone-related meningioma.
1. Known or suspected pregnancy, unexplained vaginal bleeding or endometrial hyperplasia
Patients with amenorrhea or irregular vaginal bleeding need to be excluded from pregnancy and organic lesions before they are combined with an endometrial hyperplasia.
The use of HT should be considered in conjunction with the indications for treatment of HT in patients with amenorrhea or irregular vaginal bleeding.
Vaginal bleeding can be caused by a variety of pathologies of the ovaries, fallopian tubes, uterus, cervix, and vagina.
Abnormal vaginal bleeding can occur due to lesions of the ovaries, fallopian tubes, uterus, cervix and vagina. The cause may be due to functional abnormalities, inflammation, polyps, trauma, etc.
The cause of vaginal bleeding can be due to functional abnormalities, inflammation, polyps, trauma and other benign changes, or malignant changes such as ovarian cancer, endometrial cancer and cervical cancer.
In order to avoid delaying the diagnosis and treatment, it is necessary to first clearly diagnose and exclude organic diseases.
In order to avoid delay in diagnosis and treatment, it is necessary to make a definite diagnosis first, except for organic diseases.
2. Known or suspected breast cancer
3. Known or suspected sex hormone-related malignancies
The diagnosis of breast cancer must be made first, excluding organic diseases.
tumors that may be promoted by estrogen, such as liver and kidney tumors, melanoma, etc., and tumors that may be promoted by progesterone, such as meningioma.
Progesterone may promote the growth of tumors such as meningioma.
Women with previous history of venous thromboembolism cannot or should not be treated with hormone therapy.
6. Hormone therapy is contraindicated in patients with thromboembolic disease episodes within a month.
Patients are contraindicated to use, HT.
5.Severe liver and kidney dysfunction
6, hematoporphyria (, porphyria)
This disease is a serious disorder of porphyrin metabolism due to defective enzyme activity in the hemoglobin synthesis pathway.
This disease is a serious disorder of porphyrin metabolism due to defective enzyme activity in the hemoglobin synthesis pathway.
It is an autosomal dominant disorder. It is an autosomal dominant disorder with incomplete ectopia, and is characterized by a disorder of hemoglobin synthesis under certain conditions.
The increased requirement of hepatic ferrous hemoglobin under certain conditions leads to the accumulation of porphyrin precursors in the body.
It is an autosomal dominant disease with total epiphenomenon.
7. Systemic lupus erythematosus (, SLE)
8, otosclerosis (, otosclerosis)
The contraindications for HT are also changing with the research on HT.
However, in the absence of sufficient clinical evidence, the risk associated with HT, in order to reduce the risk of HT, is constantly changing.
In order to reduce the risks associated with HT, the relevant international and national HT guidelines should be strictly observed.
In order to reduce the risks associated with HT, the relevant international and domestic HT guidelines should be strictly adhered to, and contraindications to HT should be strictly controlled to increase the safety of HT use.